In TOPARP-B, patients with tumours harbouring homozygous BRCA2 deletions demonstrated a superior median rPFS of 16.4 months vs. 5.6 months for germline BRCA1/2 mutations and 8.2 months for BRCA1/2 somatic mutations [56]. This evidence concerns the gene BRCA2 and neoplasm.